Beyond ⁶⁸Ga-labeled somatostatin analogues: is it time to say goodbye to [⁶⁸Ga]DOTA-conjugated peptides for neuroendocrine neoplasms?

Eur J Nucl Med Mol Imaging. 2023 Jul;50(8):2246-2247. doi: 10.1007/s00259-023-06275-4.

Authors

Gaia Ninatti^{1

2}, Paola Mapelli^{3

4}

Affiliations

¹ School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy. ninatti.gaia@hsr.it.
² Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, Italy. ninatti.gaia@hsr.it.
³ Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, Italy.
⁴ Vita-Salute San Raffaele University, Milan, Italy.

PMID: 37221378
DOI: 10.1007/s00259-023-06275-4

No abstract available

Publication types

Editorial
Comment

MeSH terms

Gallium Radioisotopes
Humans
Neuroendocrine Tumors* / diagnostic imaging
Organometallic Compounds*
Peptides
Positron-Emission Tomography
Receptors, Somatostatin
Somatostatin

Substances

Somatostatin
1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
Gallium Radioisotopes
Peptides
Receptors, Somatostatin
Organometallic Compounds